PUBLICATION

Magnetically powered microwheel thrombolysis of occlusive thrombi in zebrafish

Authors
Pontius, M.H.H., Ku, C.J., Osmond, M.J., Disharoon, D., Liu, Y., Warnock, M., Lawrence, D.A., Marr, D.W.M., Neeves, K.B., Shavit, J.A.
ID
ZDB-PUB-240227-3
Date
2024
Source
Proceedings of the National Academy of Sciences of the United States of America   121: e2315083121e2315083121 (Journal)
Registered Authors
Liu, Yang, Shavit, Jordan
Keywords
microparticles, stroke, thrombosis, zebrafish
MeSH Terms
  • Animals
  • Mammals
  • Plasminogen
  • Stroke*
  • Thrombolytic Therapy
  • Thrombosis*/therapy
  • Tissue Plasminogen Activator/pharmacology
  • Tissue Plasminogen Activator/therapeutic use
  • Zebrafish
PubMed
38408253 Full text @ Proc. Natl. Acad. Sci. USA
Abstract
Tissue plasminogen activator (tPA) is the only FDA-approved treatment for ischemic stroke but carries significant risks, including major hemorrhage. Additional options are needed, especially in small vessel thrombi which account for ~25% of ischemic strokes. We have previously shown that tPA-functionalized colloidal microparticles can be assembled into microwheels (µwheels) and manipulated under the control of applied magnetic fields to enable rapid thrombolysis of fibrin gels in microfluidic models of thrombosis. Transparent zebrafish larvae have a highly conserved coagulation cascade that enables studies of hemostasis and thrombosis in the context of intact vasculature, clotting factors, and blood cells. Here, we show that tPA-functionalized µwheels can perform rapid and targeted recanalization in vivo. This effect requires both tPA and µwheels, as minimal to no recanalization is achieved with tPA alone, µwheels alone, or tPA-functionalized microparticles in the absence of a magnetic field. We evaluated tPA-functionalized µwheels in CRISPR-generated plasminogen (plg) heterozygous and homozygous mutants and confirmed that tPA-functionalized µwheels are dose-dependent on plasminogen for lysis. We have found that magnetically powered µwheels as a targeted tPA delivery system are dramatically more efficient at plasmin-mediated thrombolysis than systemic delivery in vivo. Further development of this system in fish and mammalian models could enable a less invasive strategy for alleviating ischemia that is safer than directed thrombectomy or systemic infusion of tPA.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping